TRAJENTA® maintained HbA1C reductions up to 102 weeks.

TRAJENTA® has demonstrated sustained efficacy up to 2 years.1 Patients with type 2 diabetes (T2D) can be kept on 5 mg once-daily TRAJENTA® for effective control.1

Adjusted mean HbA1c change from baseline at 24 weeks in high baseline patients*1

SE: Standard error.

*Open-label extension of 4 double-blind, randomised, controlled trials over 24 weeks. Patients randomised to linagliptin treatment for the first 24 weeks continued on linagliptin for an extension of 78 weeks. The analysis shown is restricted to this arm of the trial. Analysis of secondary endpoint in FAS (observed cases).